PDCD1 and neoplasm: Tumor cells evade host immune attack by expressing several checkpoint inhibitors, such as programmed cell death-1 (PD-1) ligands (PD-L1 and PD-L2) which inhibit PD-1+ lymphocytes in tumor microenvironment (188).